For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts

Blog
The current state of pharmaceutical tariffs
Background Amid the Trump trade upheaval, pharmaceutical products receive different treatment than many other US imports. Pharmaceuticals are treated differently for reasons such as their…

DC Journal
Point: Medicaid Work Requirements Are a Common-Sense Reform
Medicaid is the government program that is supposed to help the poor afford health care. Its cost to taxpayers has skyrocketed in the last few…

Blog
Congress considers micromanaging PBM finances
With the first reconciliation bill behind it, Congress is now looking to reform other aspects of the health care system. Pharmacy Benefit Manager (PBM)…
Search Posts
Newsletter
Cancer Treatment, Global Warming Doublespeak and Counting All the Votes in NY
Shares of Dendreon Corp. rise as analysts look forward to new data on its experimental prostate cancer drug, Provenge. Public relations practitioners complain of scientists…
Newsletter
Cancer Drugs, Voting Rights and Cap and Trade Controversy
Author Virginia Postrel details her successful battle against breast cancer. The Justice Department re-considers whether the proposed D.C. voting rights bill is constitutional. States with…
Newsletter
Absurd Product Bans, Global Warming Legislation and Unsafe Organic Farming
Industry observers look to California to take the lead in ending the ban on online gambling. Reps. Henry Waxman and Ed Markey introduce sweeping new…
Blog
Virginia Postrel on Her Own Brush with Cost-Effective Drug Research
One letter writer argues that Herceptin was a poor example because "Multiple cost-effectiveness analyses have shown that, despite its high cost, Herceptin is both effective…
Op-Eds
Supreme Court Botches Preemption Case
SUPREME COURT BOTCHES PREEMPTION CASE…
Newsletter
AIG’s Tarnished Brand, The White House Vegetable Garden and Global Warming Negotiations
The damage to AIG’s corporate brand may hinder its ability to repay bailout loans from taxpayers. First Lady Michelle Obama announces the creation of a…